These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31916060)

  • 41. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
    Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
    Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
    Orlin A; Hadley D; Chang W; Ho AC; Brown G; Kaiser RS; Regillo CD; Godshalk AN; Lier A; Kaderli B; Stambolian D
    Retina; 2012 Jan; 32(1):4-9. PubMed ID: 21878851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration.
    Smailhodzic D; Klaver CC; Klevering BJ; Boon CJ; Groenewoud JM; Kirchhof B; Daha MR; den Hollander AI; Hoyng CB
    Ophthalmology; 2012 Feb; 119(2):339-46. PubMed ID: 22133792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
    Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene-gene interactions of CFH and LOC387715/ARMS2 with Korean exudative age-related macular degeneration patients.
    Kim YH; Kim HS; Mok JW; Joo CK
    Ophthalmic Genet; 2013 Sep; 34(3):151-9. PubMed ID: 23289807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The genetic variant rs4073 A→T of the Interleukin-8 promoter region is associated with the earlier onset of exudative age-related macular degeneration.
    Hautamäki A; Seitsonen S; Holopainen JM; Moilanen JA; Kivioja J; Onkamo P; Järvelä I; Immonen I
    Acta Ophthalmol; 2015 Dec; 93(8):726-33. PubMed ID: 26154559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. C-reactive protein and complement factor H polymorphism interaction in advanced exudative age-related macular degeneration.
    Soheilian R; Jabbarpour Bonyadi MH; Moein H; Babanejad M; Ramezani A; Yaseri M; Soheilian M
    Int Ophthalmol; 2017 Oct; 37(5):1161-1168. PubMed ID: 27778189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The IL-8, VEGF, and CFH polymorphisms and bevacizumab in age-related macular degeneration.
    Hautamäki A; Kivioja J; Seitsonen S; Savolainen ER; Liinamaa MJ; Luoma A; Järvelä I; Immonen I
    Ophthalmology; 2014 Apr; 121(4):973-973.e1. PubMed ID: 24534755
    [No Abstract]   [Full Text] [Related]  

  • 51. Extramacular drusen are highly associated with age-related macular degeneration, but not with CFH and ARMS2 genotypes.
    Ersoy L; Schick T; de Graft D; Felsch M; Hoyng CB; den Hollander AI; Kirchhof B; Fauser S; Liakopoulos S
    Br J Ophthalmol; 2016 Aug; 100(8):1047-51. PubMed ID: 26614632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
    Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
    Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Susceptibility to advanced age-related macular degeneration and alleles of complement factor H, complement factor B, complement component 2, complement component 3, and age-related maculopathy susceptibility 2 genes in a Mexican population.
    Buentello-Volante B; Rodriguez-Ruiz G; Miranda-Duarte A; Pompa-Mera EN; Graue-Wiechers F; Bekker-Méndez C; Ayala-Ramirez R; Quezada C; Rodríguez-Loaiza JL; Zenteno JC
    Mol Vis; 2012; 18():2518-25. PubMed ID: 23112567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distribution of risk alleles in patients with age-related macular degeneration.
    Nielsen MK; Subhi Y; Molbech CR; Grønskov K; Sørensen TL
    Dan Med J; 2020 Mar; 67(3):. PubMed ID: 32138827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Nikkhah H; Bonyadi M; Soheilian M
    Acta Ophthalmol; 2018 Mar; 96(2):e105-e110. PubMed ID: 28593728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Significance of C2/CFB variants in age-related macular degeneration and polypoidal choroidal vasculopathy in a Japanese population.
    Nakata I; Yamashiro K; Yamada R; Gotoh N; Nakanishi H; Hayashi H; Akagi-Kurashige Y; Tsujikawa A; Otani A; Saito M; Iida T; Oishi A; Matsuo K; Tajima K; Matsuda F; Yoshimura N
    Invest Ophthalmol Vis Sci; 2012 Feb; 53(2):794-8. PubMed ID: 22232432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.
    Finger RP; Wickremasinghe SS; Baird PN; Guymer RH
    Surv Ophthalmol; 2014; 59(1):1-18. PubMed ID: 24332379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration.
    van Asten F; Rovers MM; Lechanteur YT; Smailhodzic D; Muether PS; Chen J; den Hollander AI; Fauser S; Hoyng CB; van der Wilt GJ; Klevering BJ
    Ophthalmic Epidemiol; 2014 Dec; 21(6):347-55. PubMed ID: 25157998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age-related macular degeneration and association of CFH Y402H and LOC387715 A69S polymorphisms in a Turkish population.
    Soysal Y; Inan UÜ; Küsbeci T; Imirzalioğlu N
    DNA Cell Biol; 2012 Mar; 31(3):323-30. PubMed ID: 21790300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration.
    Klein ML; Francis PJ; Rosner B; Reynolds R; Hamon SC; Schultz DW; Ott J; Seddon JM
    Ophthalmology; 2008 Jun; 115(6):1019-25. PubMed ID: 18423869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.